Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine Maintenance After Allo-SCT for CML
NCT00813124Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2008
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2008; status: completed.
02
Drugs
azacitidine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00813124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813124.